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ABSTRACT 
 Recent literature has established environmental pollutants to be associated 
with health risk. However, it remains unclear whether the less studied 
organophosphate (OP) pesticides and polycyclic aromatic hydrocarbons (PAH) 
influence cardiometabolic health independent of BMI. The first study in this thesis 
used 2,227 participants from the National Health and Nutrition Examination Survey 
(NHANES). It was demonstrated that most OPs are associated with a detrimental 
cardiometabolic health outcome with higher BMIs amplifying health risk. However 
one metabolite (dimethylphosphate) was associated with advantageous health 
outcomes. In the second study, 6,159 NHANES participants were used to demonstrate 
that high levels of PAH are positively and negatively associated with obesity. PAH 
was also associated with a greater risk of metabolic syndrome, dyslipidemia, 
hypertension, and type 2 diabetes, independent of BMI. Thus, OP and PAH influence 
obesity-related health risk, however, more research is needed to further elucidate the 
mechanistic pathways associated with OP, PAH and health. 
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CHAPTER 1.0 GENERAL INTRODUCTION 
 Cardiovascular disease (CVD) is the leading cause of death in the United States 
(1) and the world (2). The economic burden of CVD is astronomical, costing the U.S an 
estimated 500 billion dollars in direct and indirect costs in 2010 (3).  Health conditions 
including type 2 diabetes (T2D), hypertension, dyslipidemia, metabolic syndrome 
(MetS), inflammation, and obesity are major risk factors for CVD (4). Due to its high 
economic burden and its relation to disease and mortality, researchers have attempted to 
identify the risk factors associated with CVD. The overwhelming majority of studies have 
focused on demonstrating the significant influence health behaviours such as diet and 
physical activity has on CVD (5,6), however, other possible factors contributing to 
cardiometabolic health has gone largely unnoticed.  
The environment is one aspect of cardiovascular health that has received less 
attention. With the increased frequency and quantity of pesticide use, the likelihood of 
exposure to such pollutants by the general public is high. Of the few studies examining 
the effects of pesticides and environmental pollutants on health, the majority report 
detrimental health effects associated with high exposure. For example, Brook et al. report 
on the negative impact of air pollution on CVD in a comprehensive literature review (7). 
Persistent organic pesticides (pesticides that remain in the environment for long periods 
of time) have also been found to increase health risk for T2D, obesity (8) and even CVD 
(9).  
However, non-persistent pesticides such as organophosphates (OPs) and certain 
environmental pollutants such polycyclic aromatic hydrocarbons (PAH) have not been 
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examined to the extent of some of their counterparts. This thesis will investigate: 1) the 
influence of OP pesticide on the relationship between body mass index (BMI) and 
cardiometabolic health risk; 2) the association between obesity and PAH in the general 
population and whether PAH influence the relationship between BMI and T2D, 
dyslipidemia, hypertension, and MetS.   
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CHAPTER 2.0 REVIEW OF RELATED LITERATURE 
Introduction on Organophosphate Pesticide 
The OP class of insecticides gained popularity after the outlawing of 
organochlorine based pesticides in 1972 (10). OPs are primarily utilized in agricultural 
settings but are also available to the public for residential use. The wide array of 
commercial and residential access to this pesticide makes exposure to the general public 
unavoidable (11).   
OPs are highly effective and, unlike the persistent organochlorine based pesticides 
such as DDT, have the ability to quickly degrade through hydrolysis when they come into 
contact with sunlight, soil or air (12). Although easily degraded, OPs maintain high acute 
affectivity which is due to the pesticides immediate targeting of the central nervous 
system (12). In specific, the OP pesticide inhibits the production of acetylcholinesterase, 
an enzyme needed to break down acetylcholine, causing the accumulation of poisonous 
levels of acetylcholine in the synaptic cleft (11). This compromises the neurons ability to 
communicate with neighboring neurons, leading to impaired motor functions and 
ultimately resulting to death in insects (11). Fortunately, humans and large mammals 
have the ability to process and expel the pesticide from their system within hours or days 
after exposure (12). The unique characteristics of OPs make them a prime candidate for 
use around the world, increasing their likelihood of influence on human health.  
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Figure 1: Chemical structures of each DAP metabolite (Kavvalakis & Tsatsakis, 2012) 
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Organophosphate Pesticide  
 
In epidemiological research, there are 6 commonly studied urinary metabolites of 
OP pesticide exposure known as dialkyl phosphates (DAPs; Figure 1). These compounds 
are primarily made up of esters, amides or thiol derivatives of phosphoric, phosphonic, 
phosphorothioic, or phosphonothioic acids (13). The DAPs are classified into 3 
dimethylphosphate metabolites  (dimethylphosphate (DMP), dimethythiophosphate 
(DMTP), and dimethyldithiophosphate (DMDTP)) and 3 diethylphosphate metabolites 
(diethylphosphate (DEP), diethythiophosphate (DETP), and dietheyldithiophosphate 
(DEDTP)). Biomonitoring of OP pesticides are mostly completed through urinary 
analysis, but can also be measured in sweat, blood, hair and amniotic fluid.  It is 
important to note that long-term exposure, or an accumulation of exposure, is best 
measured through hair samples (12). 
 
Organophosphate Pesticide and Glucose Markers 
A number of studies have established a relationship between OP and glucose 
indicators (8,14–21). High levels of OP is believed to damage the pancreas and cause 
acute pancreatitis by increasing oxidative stress (22). These effects of OP on the pancreas 
may lead to abnormal blood glucose levels (22). Consequently, a large number of animal 
studies and a select few human trials have reported OP exposure to be related with 
increases in plasma glucose (14–16,18,20). For instance, Malekirad et al. compared 187 
farmers exposed to OP pesticide with 187 matched controls, and discovered that farmers 
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exposed to OP had significantly higher fasting blood glucose and glucose tolerance test 
levels compared to the control group (16).  
In addition to the aforementioned study, a study examining over 30,000 licensed 
pesticide applicators observed OP pesticide exposure to increase the risk for T2D (17). 
OP exposure is also related to higher insulin levels (18) and insulin resistance (18,19). 
Although previous literature has established links between OP and diabetes markers, 
many of these findings were observed in animal subjects. In addition, the limited studies 
conducted on humans focused primarily on individuals directly exposed to high quantities 
of the pesticide, such as farmers (16,19) and pesticide applicators (17), with none 
studying the general public. Further, two out of the three human studies used self-report 
data to quantify pesticide exposure (16,17), with only one directly measuring pesticide 
levels (19). Thus, it remains unclear whether lower OP rates measured in the general 
population would result in similar observations. 
 
Organophosphate Pesticide and Blood Lipids 
Previous studies have demonstrated inconsistent findings regarding the 
relationship between OP and blood lipids. For instance, a study conducted on male albino 
rats observed a significant decrease in HDL after the administration of different doses of 
OP pesticide (23). On the other hand, Abdou and El Mazoudy administered OP to 35 
female Sprague-Dawley rats and found that exposure resulted in significant increases in 
HDL (24). There are a number of studies in animals indicating that exposure to OP 
results in significantly lower (15,23), significantly higher (24–26), and no significant 
  
7 
difference in HDL (27). Considering the important role HDL has on cardiometabolic 
health, it is essential to clarify these inconsistent findings and to further investigate this 
relationship in humans.  
Unlike HDL, the deleterious effects of OP on triglyceride are well established in 
animals. For instance, a study on overnight-fasted rats found significant increases in 
triglyceride 8, 12, and 24 hours post OP pesticide exposure, compared to controls (15). In 
addition, a number of other animal studies have also found OP pesticide to be associated 
with increased triglyceride levels (23–25). Mechanisms for such findings are unclear, but 
it is believed that OP pesticides inhibit the lipase activity of hepatic triglycerides and 
plasma lipoproteins affecting the physiology of HDL and triglyceride within the body 
(23).  
In summary, there is clearly an association between blood lipids and OPs, 
however we are unable to extrapolate any conclusions as to whether these results will 
translate to humans. Therefore we are in need of research specifically investigating these 
relationships in humans to asses whether low levels of OP found in the general public 
will match previous literature on animals. 
 
Organophosphate Pesticide and Blood Pressure 
OP has been previously reported to increase blood pressure in rodents.  One study 
observing 90-day old male rats found that after the administration of a number of 
different doses of OP, exposed rats had a 15-20 mmHg increase in blood pressure (28). A 
second study concluded that rats with pre-existing hypertension exhibit even higher blood 
  
8 
pressure after the administration of OP pesticide (29). The only publication observing this 
relationship in humans demonstrated that acute ingestion of OP was associated with both 
prevalent hypo and hypertension, however, no baseline measures were taken to quantify 
the difference between blood pressure levels before and after OP ingestion (30).  
Gordon and Padnos have proposed that this increase in blood pressure may have 
little to do with cardiac output and more to do with an increase in peripheral resistance. 
The alterations in blood pressure were suggested to have been the result of the pesticide’s 
ability to directly influence the central and peripheral nervous system pathways (28). 
Nevertheless, in order for us to deduce any concrete conclusions about the effects of OP 
on blood pressure, we require more research.  
 
Organophosphate Pesticide and Weight Gain 
Lastly, OP is believed to lead to weight gain and obesity (8,19,21,31). In general, 
rats exposed to low-levels of OP pesticide exhibit an increase in weight and adipose 
tissue mass compared to controls (31). OP exposure has also been found to be positively 
associated with increases in waist circumference (WC) in a group of OP exposed farmers 
(19). It is argued that OP may be disrupting the endocrine system in the body resulting in 
weight gain (31), however there is little evidence for this theory. Although there is a 
proven association between obesity and health risk, there is large variation in how 
obesity-related comorbidities are expressed.  It is unclear whether OP-related weight gain 
is similarly associated with detrimental health outcomes.  To our knowledge, no studies 
have investigated whether OP influences the relationship between health risk and obesity. 
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Summary of Organophosphate Pesticide 
 For the most part, it is well established that OP is related to negative health 
outcomes. However, the overwhelming majority of previous literature has concluded 
findings based primarily on animal subjects with studies examining human participants 
being far and few in between. The few examining OP and health in humans have placed 
focus on individuals with direct high exposure to the pesticide, typically through their 
occupation, with more common exposure levels observed in the general population being 
scarcely studied.  
Specific Aims: 
Aim 1: To investigate whether OP influences the relationship between BMI and 
cardiometabolic health risk.  
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Introduction to Polycyclic Aromatic Hydrocarbons  
 Particulate matter, nitrogen oxides, carbon monoxide, and sulfur dioxide are 
amongst the most commonly known 
and studied environmental pollutants. 
Conversely, one pollutant that has 
received less attention is PAH. This 
particular environmental pollutant is 
formed during the incomplete 
combustion of organic substances such 
as oil, gas, wood, and coal. PAH are 
naturally released into the environment through volcanic eruptions and natural forest 
fires, however humans also contribute to PAH production via activities such as burning 
of wood and the release of vehicular exhaust into the environment. PAH can be found on 
charred or grilled meat or in foods such as rice, flour and vegetables grown in spaces 
where the air or soil is polluted. (32) 
Inhalation is the most common method of exposure, however PAH can enter the 
body through the ingestion of contaminated food or water, or through direct skin contact 
with polluted soil or other contaminated materials (32). In addition, there is a high 
positive correlation between certain PAH biomarkers and smoking (33,34), wherein 
individuals who are exposed to tobacco smoke have shown markedly increased levels of 
PAH in their urine. Although there are a number of different methods of exposure, 
Figure 2: Chemical structures of 4 PAH 
  
11 
exposure through inhalation is believed to be more readily absorbed by the body, while 
ingestion shows less absorption (32).  
The National Waste Minimization Program (NWMP) reported 31 priority 
chemicals that they deem toxic and harmful (35). Naphthalene, fluorene, phenanthrene 
and pyrene are all amongst the priority chemicals listed by NWMP. The basic chemical 
structures of the 4 PAH mentioned above are illustrated in Figure 2. Once exposed, the 
body processes the chemicals and expels the compounds in its hydroxylated form (36). 
Urinary metabolites of these chemicals are a reliable indication of exposure to 
environmental PAH (36–42), which is why NHANES has initiated the biomonitoring of 
PAH in the urine starting from the 2001 survey year. In specific, NHANES provides 
participant information on a number of metabolites including 1-naphthalene, 2-
naphthalene, 1-fluorene, 2-fluorene, 1-phenanthrene, 2-phenanthrene, 3-phenanthrene, 
and 1-pyrene. 
 
Polycyclic Aromatic Hydrocarbons and Obesity 
 Evidence for the relationship between PAH and obesity is lacking with only two 
studies conducted on youth and none performed on adults. A study by Rundle et al. found 
that children whose mothers were in the highest tertile of PAH exposure during 
pregnancy had significantly greater BMI z-scores, and a 79-126% greater risk of obesity 
compared to children whose mothers were exposed to lower levels (43). Furthermore, 
using the NHANES datasets, a study examining over 3,000 children found PAH 
metabolites to be associated with a higher BMI z-score and WC in children aged 6-11 
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years old (44). Although this relationship has been demonstrated in children, it remains 
unclear whether PAH is also positively associated with obesity in the adult population.  
 
Polycyclic Aromatic Hydrocarbons and Type 2 Diabetes  
 In 2030, the prevalence of T2D in adults is projected to rise 69% in developing 
countries and 20% in developed countries (45) increasing the burden of diabetes and the 
complications associated with it. Although physical activity, diet, and obesity are well-
known risk factors of this chronic disease, recent literature has also established certain 
persistent organic pollutants to be contributing to the increasing prevalence of T2D (46–
48). In addition, PAH increases inflammation in the body (49,50), which is also linked to 
a greater risk of CVD and T2D (51).  
Alshaarawy and colleagues are currently the only researchers to have investigated 
the association between PAH and T2D. In specific, they observed a positive association 
between 3 urinary PAH metabolites and T2D, independent of BMI (49). However, with 
the previous study being the only known study examining this relationship, further 
research is needed to substantiate these findings.  
 
Polycyclic Aromatic Hydrocarbons and Blood Lipids 
 Elevated levels of low-density lipoprotein cholesterol (LDL) and serum 
triglyceride (52,53), and low levels of high-density lipoprotein cholesterol (HDL) (54) are 
major risk factors for coronary heart disease (CHD) and CVD (4). It is suggested that 
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over 50% of the U.S adult population has some form of blood lipid abnormality (55). 
Environmental pollutants such as PAH may be just one non-traditional risk factor related 
to abnormal blood lipid levels. 
 Using the NHANES 1999-2006 survey years, it was demonstrated that certain 
environmental pollutants were related to abnormal HDL, LDL and triglyceride levels 
(56). However for the specific PAH pollutant, it was observed that a couple of PAH 
biomarkers were related to 3% lower levels of HDL, independent of BMI, while no 
significance was observed for PAH and other blood lipids. Unfortunately, to our 
knowledge, this was the only study examining PAH and blood lipids. Thus, questions still 
remain as to whether PAH has a significant association with blood lipids in humans.  
 
Polycyclic Aromatic Hydrocarbons and Cardiac Health 
 The American Heart Association estimates the prevalence of CVD to increase to 
40% and the economic burden to triple by the year 2030 (57). The increased prevalence 
and financial projections are worrisome, prompting the investigation of possible factors 
related to the development of CVD and other cardiac-related illnesses. Previous literature 
has reported PAH to augment the risk of death by ischemic heart disease by 20-40% (58) 
and to be associated with peripheral arterial disease (59). In addition, 3,283 adults were 
examined by Xu et al. and it was found that PAH is strongly associated with self-reported 
CVD (60). The effects of PAH on cardiac health are reflected clearly in the literature, 
however very limited studies have focused on the conditions known to be major risk 
factors for cardiac-related illnesses such as hypertension, T2D and dyslipidemia.  
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Summary of Polycyclic Aromatic Hydrocarbon Literature 
 It is well established that CVD is strongly related to a number of different health 
conditions including obesity, T2D, and dyslipidemia. Previous literature has established a 
clear link between PAH and CVD, however there is very limited literature published on 
CVDs major risk factors and comorbidities including obesity, T2D and dyslipidemia. 
Therefore, we are in need of more research to help grow the limited literature currently 
published in the field.  
Specific Aims: 
Aim 1: To investigate whether PAH is associated with obesity. 
Aim 2: To examine whether PAH influences the relationship between BMI and 
metabolic syndrome (MetS), T2D, hypertension and dyslipidemia.  
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CHAPTER 3.0 MANUSCRIPT 1 
 
 
The Influence of Urinary Concentrations of Organophosphate Metabolites on the 
Relationship between BMI and Cardiometabolic Health Risk 
 
Organophosphates (OP) are one of the most common types of pesticide used around 
the world (61). OP pesticides can enter the body through ingestion, inhalation, as well as 
direct contact with the skin (11,12).  Once in the body, the liver processes the pesticide 
and its metabolites are excreted through the urine (11). The metabolites produced are 
unique for each pesticide, with the most commonly studied being dimethylphosphate 
(DMP), dimethylthiophosphate (DMTP), dimethyldithiophosphate (DMDTP), 
diethylphosphate (DEP), diethylthiophosphate (DETP) and diethyldithiophosphate 
(DEDTP) (62). 
Previous literature has demonstrated OP pesticide exposure to be associated with 
elevated cardiometabolic risk such as increased triglycerides (15,23–25), HDL (15,23), 
hyperglycemia (14–17,19,20), and blood pressure (28–30). In addition, positive 
associations between weight gain and OP pesticides have also been demonstrated 
(8,19,21,31). However, the majority of studies were performed on animals or individuals 
with high occupational OP pesticide exposure and it is unclear whether lower levels of 
OP more commonly observed in the general population are also associated with adverse 
health effects.  Furthermore, as obesity is associated with negative health outcomes, it is 
also unclear if the influence of OP pesticide on cardiometabolic health risk remains 
independent of BMI.  
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Therefore, the main objective of this study is to determine whether OP metabolites 
modify the relationship between cardiometabolic health risks and BMI in the general U.S 
population. 
RESEARCH DESIGN AND METHODS 
National Health and Nutrition Examination Survey (NHANES) 
NHANES is a national survey that aims to collect health and diet information 
from a representative sample of the non-institutionalized U.S. population. NHANES 
continuous (1999-2013) utilizes a multifaceted probability sampling design that places 
importance on the oversampling of minority populations. All participants provided 
written informed consent in agreement with the Public Health Service Act prior to any 
data collection. Information was acquired from participants through household 
questionnaires, telephone interviews, and examinations conducted by health care 
professionals and trained personnel. Data examined in this study was the public use 
microdata file accessed from the Center for Disease Control and Prevention (CDC) 
website (63). Information on NHANES survey methods are described in greater detail 
elsewhere (64,65).  
Study Participants and Exclusion Criteria 
A total of 51 623 participants were examined during the 1999-2008 survey years. 
Within this population, NHANES randomly selected a sub-sample of 12 273 survey 
participants for assessment of OP pesticide exposure using urinary concentrations of six 
types of dialkyl phosphate (DAP) metabolites. Individuals <20 years of age (n=5452) or 
pregnant participants (n=417) were excluded from the study resulting in 6467 
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participants. Individuals with a fasting duration of less than 3 hours or more than 24 
hours (n=1231) or those with missing or outlier measurements for high-density 
lipoprotein cholesterol (HDL; n=296), low-density lipoprotein cholesterol (LDL; 
n=3626), total cholesterol (n=296), serum triglyceride (n=3467), plasma glucose 
(n=3443), serum insulin (n=3483), glycohemoglobin (HbA1c; n=243), homeostatic 
model assessment of insulin resistance (HOMA-IR; n=3488), systolic blood pressure 
(SBP; n=289), diastolic blood pressure (DBP; n=322), C-reactive protein (CRP; n=277) 
or body mass index (BMI; n=120) were also excluded. In addition, missing and outlier 
values for urinary creatinine (n=4), smoking status (n=6), and PIR (n=491) were 
excluded. One individual with an extreme outlier of 2800 ug/L for DMTP was also 
excluded leaving a total of 2245 participants remaining participants. Finally, the mean 
caloric intake was substituted for all individuals with missing caloric intake values 
(n=278) resulting in 2227 participants available for analysis.  
Assessment of Organophosphate Pesticide Exposure 
 A multi-stage approach was employed for the storage, transportation and 
measurement of each OP metabolite. Urine specimens were collected and immediately 
stored at -20°C or lower. Samples were then placed over dry ice and transported to the 
Division of Laboratory Sciences, National Center for Environmental Health, Centers for 
Disease Control and Prevention. Specimen samples that contained less than 0.5 ml of 
urine were discarded due to the possible occurrence of errors during processing.  Urine 
samples were brought to room temperature and spiked with stable isotope analogues of 
the specific DAP metabolite being measured, which provided a reliable internal control, 
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and a lyophilizer was then used to remove excess water from the urine sample. The 
remaining products were mixed with acetonitrile and dietyl ether, and were chemically 
derivitized to their individual chloropropyl phosphate esters. Finally, gas 
chromatography-tandem mass spectrometry was used to assess each individual 
chloropropyl phosphate esters. These methods are described in greater detail elsewhere 
(61,66). 
Sufficient metabolite concentrations were required for the instruments to 
accurately detect the OP metabolites, with instrument sensitivity varying depending on 
survey year. Values below the detection limit were replaced with a value equal to the 
detection limit divided by the square root of two. For this study, the survey year with the 
highest detection limit was used as the cut-off value for each metabolite, dichotomizing 
participants into those above and below metabolite detection limit. 
Cardiometabolic Risk Factors  
Cardiometabolic risk factors were analyzed using a number of different 
techniques. In general, trained phlebotomists at mobile examination centers (MEC) 
obtained blood samples from survey participants. CRP was obtained through latex-
enhanced nephelometry of blood specimens (67). The hexokinase method and 
Roche/Hitachi analyzer were used to evaluate blood plasma glucose (68), while blood 
HbA1c and insulin levels were obtained by ion exchange high-performance liquid 
chromatography using the Primus apparatus (69) and the immunoassay method, 
respectively (70). HOMA-IR was calculated by dividing the product of fasting plasma 
glucose (mmol/L) and insulin (mU/L) by 22.5. Hitachi analyzers were used to quantify 
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triglyceride, total cholesterol and HDL levels throughout the survey years while LDL was 
calculated using the Friedewald equation (71–73). Blood pressure was measured 3 times 
with some individuals being evaluated 4 times in the event of equipment or technician 
error. For this study, the mean of all available DBP and SBP measurements was used 
during analysis. A more detailed explanation of the methods can be found online (63). 
Statistical Analysis 
Participant characteristics by OP metabolite detection limit status were examined 
using chi-square tests for categorical variables and t-tests for continuous variables. 
Continuous variables are presented as means ± standard error (SE) while the prevalence 
(N, %) was presented for categorical variables. Multiple regression analysis was 
performed to assess the association between OP metabolites and BMI. Each regression 
model was adjusted for potential confounders including age, sex, ethnicity, PIR, smoking 
status, fasting duration, total caloric intake and urinary creatinine levels to account for 
urinary dilution level (64). All regression models included an interaction term between 
BMI and OP metabolites. If no significant interaction was observed, the interaction term 
was excluded and main effects were examined with adjusted least square means (LSM) ± 
SE being computed to illustrate the differences in cardiometabolic health risk by OP 
metabolite detection status. All data analyses used SAS version 9.3 survey procedures 
including appropriate weights to adjust for unequal sampling probabilities and to allow 
representation of the U.S population. A value of p < 0.05 was used as the criterion for 
significance. 
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RESULTS 
Participant characteristics by OP metabolite detection status are presented in 
Table 1. In general, those with detectible OP metabolites were significantly older than 
those below detection (with the exception of DETP and DEDTP). In addition, BMI was 
significantly (P < 0.0001) associated with all observed cardiometabolic health risk factors 
after adjustment for confounders. 
Table 2 illustrates the association between OP metabolites and cardiometabolic 
health risks after adjusting for confounders. DBP was observed to be significantly higher 
for individuals with detectible DMP, DEP or DEDTP (P < 0.05) while no significant 
difference was observed for DMTP, DMDTP, or DETP. Further, individuals with 
detectible DMTP had significantly lower total cholesterol and LDL than those without 
detectible levels, while no significant differences were observed for CRP, HOMA-IR, 
HbA1c, plasma glucose or SBP (P > 0.05). 
Figure 1 presents the association between HDL and BMI by OP metabolite 
detection limit status after adjustment for confounders. Individuals with detectible DMTP 
had significantly higher HDL than those below detectible levels (P = 0.01). Contrarily, 
those with detectible DEDTP had significantly lower HDL levels than those below 
detection (P = 0.01).  Individuals with detectible DEP and DETP exhibited lower HDL at 
the higher BMI range, while a marginal difference was observed between OP metabolite 
detection statuses at lower BMIs (Interaction effect: P = 0.034 and P = 0.0153, 
respectively).  No significant interactions or main effects were observed with DMP or 
DMDTP and HDL (P > 0.05). 
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Figure 2 demonstrates the relationship between triglyceride and BMI by OP 
metabolite detection limit status after adjusting for confounders. Individuals with 
detectable DMDTP exhibited significantly higher triglyceride levels than those below 
detection (Main Effect: P = 0.05). In addition, there was a significant interaction effect 
between DETP and BMI (P = 0.02), wherein individuals with detectible DETP had 
higher triglyceride levels than those below detection at higher BMI ranges and only a 
minimal difference at lower BMIs. There were no significant interactions or main effects 
for DMP, DMTP, DEP, or DEDTP metabolites (P > 0.05). 
BMI was positively associated with insulin levels. Individuals with detectible 
DEP had higher insulin levels than those below detection at the higher BMI range with 
smaller differences at a lower BMI. (Figure 3; P = 0.0191). No significant associations 
were observed with the other metabolites and insulin (P > 0.05). 
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DISCUSSION 
 To our knowledge, we are the first to investigate the influence of urinary OP 
metabolites on the relationship between BMI and cardiometabolic health risk in the 
general population. We demonstrated that individuals with detectible OP metabolites 
most commonly have an augmentation of obesity-related cardiometabolic health risk. 
However, DMTP was associated with a healthier lipid profile for a given BMI. 
Consequently, these findings suggest that detectible OP metabolite levels in the general 
population may confer both adverse and advantageous health outcomes, thus highlighting 
the importance of examining each metabolite individually when studying the effects of 
OP metabolites on health. 
Several studies have demonstrated significant findings in respect to OP pesticide 
and glucose markers (8,14–21). In general, it is believed that OP pesticide directly effects 
the functioning of the pancreas leading to an altered glucose profile (22). Consequently, a 
large number of animal and human studies have observed OP pesticide exposure to be 
associated with significant increases in plasma glucose (14–16,18,20), insulin (18), 
insulin resistance (18,19) and incidence of type 2 diabetes (17). Although previous 
literature has established links between OP pesticide exposure and diabetes biomarkers, 
we observed that only DMDTP was associated with fasting insulin after adjusting for 
BMI. The lack of significance between glucose markers and OP metabolites may be 
partly due to the fact that previous investigation of human exposure to OP pesticides have 
focused primarily on individuals who are regularly exposed to high quantities of the 
pesticides through their occupation, such as farmers (16,19) and pesticide applicators 
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(17). Thus, OP exposure levels seen in the broader population may not be sufficient to 
elicit the same negative effects. 
The association between OP pesticide exposure and HDL remains unclear, with 
previous studies reporting a number of contradictory findings. Compared to controls, rats 
exposed to OP pesticides have exhibited significantly lower (15,23), significantly higher 
(24–26) , and no significant (27) effect on HDL. Mechanisms for such findings are 
unclear, but it is suggested that OP pesticides may influence lipase activity of hepatic 
triglycerides and plasma lipoproteins (23). We demonstrate that individuals with 
detectible DEDTP had 0.09 mmol/L lower HDL than those with non-detectible levels for 
a given BMI (P = 0.01). In addition, obese individuals above detection for DEP and 
DETP had 0.03-0.04 mmol/L lower HDL compared to those below detection. Based on 
previous observations(54), these findings may translate to 4-15% higher cardiovascular 
disease (CVD) mortality rates. 
Although having detectible levels of certain metabolites was associated with a 
detrimental health profile, the opposite finding was observed with the DMTP metabolite. 
In general, individuals with detectible DMTP exhibited significantly higher HDL, lower 
LDL, and lower total cholesterol than those without detectible levels. Interestingly, these 
findings are not completely uncommon with previous reports demonstrating that OP 
pesticide exposure decreases LDL in normolipidemic and hyperlipidemic rats (26) and 
rabbits (25). As previously discussed, a number of studies have also observed higher 
HDL levels (24–26) in OP pesticide exposed participants. Although interesting, it 
remains unclear why this specific metabolite resulted in a more favorable lipid outcome; 
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however, we believe that these findings place emphasis on the unique physiological 
effects of each specific OP metabolite.  Thus, we are in need of further research 
examining the possible etiology and physiology of DMTP within the body to advance our 
understanding of these outcomes. 
Previous work on rodents has examined the relationship between OP pesticide 
exposure and blood lipids with reports that OP pesticide exposed rats exhibit significantly 
higher triglyceride levels than controls (15,23–25). Consistent with these studies on rats, 
we demonstrate that individuals with detectible DMDTP have 0.09 mmol/L higher serum 
triglyceride levels than those below detection, independent of BMI (P = 0.05). Further, 
obese individuals with detectible DEP had 0.17 mmol/L higher triglyceride than those 
below detection which translates to a 5-13% higher risk of CVD (53). Thus, certain OP 
metabolites foster unfavorable triglyceride levels, which may modestly augment CVD in 
the general population, with individuals at a higher BMI range having their risk 
amplified. 
 Limited research has examined the effects of OP pesticides on blood pressure, 
however it has been reported that both low and high doses of OP pesticide is associated 
with an increase in blood pressure up to 24 hours post exposure in rats (28). In addition, 
rats with pre-existing hypertension exhibit greater blood pressure increases after the 
administration of OP pesticide (29). These findings are thought to be the result of OP 
pesticides directly effecting the central and peripheral nervous system pathways, leading 
to altered blood pressure outcomes (28). Interestingly, we observed that independent of 
BMI, individuals with detectible DMP, DEP and DEDTP metabolite levels had a 1-3 
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mmHg higher DBP (P < 0.05) than those below detection which may augment the risk of 
CHD by 4-13% (74). Therefore, independent of BMI, the association between OP 
metabolites and blood pressure may amplify risk of adverse cardiac events in the general 
population.   
 A few limitations and strengths of this study warrant mention. First, the cross-
sectional nature of the present study does not allow us to infer causation. Second, 
although several previous studies support the use of these six types of dialkyl phosphate 
metabolites as an indication of OP pesticide exposure (25,75,76), questions on the ability 
to attribute the source of urinary OP metabolites remain (77,78).  Finally, we elected to 
use more liberal detection limits to reduce the likelihood of misclassifying the exposure, 
and this study represents one of the few studies examining OP metabolite concentrations 
and health risk that is more applicable to the general public. 
 
CONCLUSIONS 
In summary, we demonstrated that having detectible levels of urinary OP 
metabolites might be associated with both advantageous and detrimental metabolic 
outcomes independent of BMI, with obese individuals having an amplification of 
cardiometabolic health risk. In addition, when studying the effects of OP metabolites on 
health, it is important to examine the influence of each OP metabolite individually as 
their effects on health may differ. Consequently, future studies need to examine the 
physiology of each metabolite, with particular attention on the obese population wherein 
health risk seems to be amplified.
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Figure 1 A-F):  Relationship between HDL and BMI by DMP (A), DMTP (B), DMDTP 
(C), DEP (D), DETP (E) and DEDTP (F) detection limit status.  
Solid black line represents individuals below the detection limit while the dotted black line 
represent individuals above the detection limit.  
ME = main effect 
Models are adjusted for PIR, ethnicity, age, sex, smoking status, urinary creatinine, fasting 
duration and total calorie intake 
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Figure 2 A-F):  Relationship between triglyceride and BMI by DMP (A), DMTP (B), 
DMDTP (C), DEP (D), DETP (E) and DEDTP (F) detection limit status. 
Solid black line represents individuals below the detection limit while the dotted black 
line represent individuals above the detection limit.  
Models are adjusted for PIR, ethnicity, age, sex, smoking status, urinary creatinine, fasting 
duration and total calorie intake 
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Figure 3 A-F):  Relationship between insulin and BMI by DMP (A), DMTP (B), 
DMDTP (C), DEP (D), DETP (E) and DEDTP (F) detection limit status. 
Solid black line represents individuals below the detection limit while the dotted black 
line represent individuals above the detection limit.  
Models are adjusted for PIR, ethnicity, age, sex, smoking status, urinary creatinine, 
fasting duration and total calorie intake 
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CHAPTER 4.0 MANUSCRIPT 2 
 
Polycyclic Aromatic Hydrocarbon Biomarkers are Associated with Obesity, 
Metabolic Syndrome, Dyslipidemia, Hypertension and Type 2 Diabetes  
 
Polycyclic aromatic hydrocarbons (PAH) are man-made environmental pollutants 
resulting from the incomplete combustion of oil, fossil fuel, gas, coal and waste, and are 
also produced naturally from volcanoes and forest fires (32). This environmental 
pollutant normally enters the body through inhalation, but can also gain entry through 
skin exposure, ingestion of charred/smoked meat, or through the ingestion of 
contaminated produce and grains cultivated from polluted soil (32). The majority of PAH 
are excreted from the body shortly after exposure, while small amounts are believed to be 
retained in fat and liver tissues (32,79). In addition, PAH may accumulate in the body 
over time (79).  
PAHs have been shown to be associated with cancer (80–86), and were recently 
linked with inflammation (49,50), fatal ischemic heart disease (58), peripheral arterial 
disease (59) and cardiovascular disease (60). A recent study of PAH in children found a 
positive correlation between high concentrations of PAH and level of obesity (87). 
However, it is unknown whether this environmental pollutant is related with obesity in 
adults and whether the associations between PAH and cardiometabolic conditions remain 
independent of BMI.  
Therefore the objectives of this study are to determine whether PAH is related 
with obesity and to investigate whether the association between PAH and metabolic 
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syndrome (MetS), hypertension, diabetes, and dyslipidemia is present, independent of 
BMI.  
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RESEARCH METHODS 
Participants 
Adult participants at least 20 years of age from the National Health and Nutrition 
Examination Survey (NHANES; 2001-2004 and 2007-2012 survey years) with available 
PAH data were included in this study. NHANES is a nationally representative survey of 
the non-institutionalized United States population with microdata available online to the 
public (63). All individuals provided written informed consent prior to participation.  
Participants were excluded from the study if they were pregnant (n=292), had a 
BMI ≥ 70 kg/m
2
 (n=2) or had missing data for BMI (n=125), poverty income ratio 
(n=525), smoking status (n=7), or creatinine (n=1). Individuals who could not be 
categorized into having or not having MetS (n=216) or dyslipidemia (n=124) due to 
missing data were also excluded resulting in 6159 remaining participants.  
Polycyclic Aromatic Hydrocarbons 
 Trained professionals at mobile examination centers collected urine samples from 
participants and stored them at -20° C or lower.  Capillary gas chromatography as well as 
high-resolution mass spectrometry was used to quantify the metabolites of interest. A 
total of 8 hydroxylated urinary PAH metabolites were observed including 1-naphthalene, 
2-naphthalene, 2-fluorene, 3-fluorene, 1-phenanthrene, 2-phenanthrene, 3-phenanthrene, 
and 1-pyrene. After performing regression analyses it was observed that the parameter 
estimates for the bottom 4 quintiles were very similar, while the top quintile differed 
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significantly. Therefore, each PAH metabolite was dichotomized into high (highest 
quintile) and low (lower 4 quintiles). 
Metabolic Syndrome, Dyslipidemia, Type 2 Diabetes and Hypertension 
Metabolic syndrome (MetS) was defined using the National Heart, Lung, and 
Blood Institute’s updated NCEP ATP III definition (88). Individuals with 3 or more of 
the following 4 metabolic risk factors were classified as having MetS. These risk factors 
included: 1) cholesterol abnormalities (HDL ≤1.03 mmol/L for men and ≤1.29 mmol/L 
for women, were on cholesterol medication, or had a doctor diagnose them with abnormal 
cholesterol levels), 2) high triglyceride levels ( ≥1.69 mmol/L), 3) high blood pressure 
(systolic blood pressure (SBP) of ≥130 mm Hg, diastolic blood pressure (DBP) ≥ 85 mm 
Hg, taking hypertension medication, or had doctor diagnosed hypertension), or 4) blood 
glucose abnormalities (fasting glucose levels of ≥ 5.6 mmol/L, taking diabetes 
medication, taking insulin, or had doctor diagnosis diabetes). Waist circumference was 
excluded as one of the possible risk factors to avoid having obesity as both the dependent 
and independent variable and allow for the examination of BMI as an independent 
variable. 
Dyslipidemia was defined as: serum triglyceride levels ≥ 2.06 mmol/L, total 
cholesterol ≥ 6 mmol/L, HDL < 1.04 mmol/L for men and < 1.29 for mmol/L for women, 
were on cholesterol medication, or had doctor diagnosed hypercholesterolemia.  Diabetes 
was defined as: fasting plasma glucose ≥ 7 mmol/L (89), plasma glycoheomoglobin 
(HbA1c) levels ≥ 6.5% (90), doctor diagnosed T2D, taking diabetes medication, or were 
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taking insulin.  Hypertension was defined as: SBP ≥ 140 mmHg, DBP ≥ 90 mmHg, 
doctor diagnosed hypertension, or taking hypertension medication (91).  
Statistical Analysis 
 Differences in participant characteristics by MetS status were examined using chi-
square tests for categorical variables and t-tests for continuous variables. The prevalence 
(N,%) was presented for categorical variables, while the mean ± standard error (SE) was 
presented for continuous variables. Multiple linear regressions and partial correlations 
were performed to study the association between BMI and standardized PAH levels 
adjusting for age, sex, ethnicity, poverty index ratio (PIR), creatinine (64), and smoking 
status. It should be noted that due to the high correlation between PAH and smoking 
(33,34), in addition to other covariates, all multivariable analysis was adjusted for the 
smoking status variable to account for the possible disadvantageous metabolic outcomes 
resulting from smoking status.  
Adjusted logistic regressions were performed to examine the association between 
MetS, hypertension, T2D, dyslipidemia and PAH. Each regression model included an 
interaction term between PAH and BMI, if no significant interaction was observed, the 
term was removed and the main effects were examined. If a significant interaction was 
observed, BMI was categorized into normal weight, overweight and obese to further 
examine the relationship between PAH and metabolic conditions by weight status. Since 
the prevalence of the outcomes of interest were greater than 10%, the ORs were 
converted to prevalence risk (PR) using a formula introduced by Zhang et al. (92).  
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SAS v. 9.4 was utilized for all 
statistical analysis, and all models except the Pearson correlations were weighted to be 
representative of the general US population with significance being observed at P ≤ 0.05.  
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RESULTS 
Table 1 presents the participant characteristics by MetS status. A total of 1265 
(20.5%) individuals were defined as having MetS. In general, those with MetS were 
significantly older (P < 0.0001), had higher BMI levels (P < 0.0001) and were more 
likely to be male (P = 0.014).  
As can be seen in Table 2, BMI was positively associated with 1-naphthalene, 2-
naphthalene and 2-phenanthrene (P < 0.05) and negatively associated with 2-fluorene, 
and 3-fluorene (P < 0.05) after adjustment for age, sex, ethnicity, PIR, smoking status, 
and creatinine.  
Figure 1A illustrates the association between the various PAH metabolites and 
MetS after adjusting for confounders. There were no significant interaction effects 
between PAH and BMI (P > 0.05).  For a given BMI, individuals in the highest quintile 
of 1-napthalene had a 25.5% greater PR of MetS than those with lower levels (P = 
0.0061). For a given BMI, individuals in the highest quintile of 3-fluorene had 26.9% 
greater PR of MetS compared to those with lower levels (P = 0.0143). No significant 
associations were observed for the other metabolites and MetS (P > 0.05).  
No interaction effects were observed for T2D (PAH x BMI interactions, P > 
0.05). For a given BMI, individuals in the highest quintiles of 1-naphthalene and 2-
naphthalene had a 52.5% (P = 0.0005) and 42.4% (P < 0.015) greater PR of T2D 
respectively (Figure 1B). For a given BMI, those in the highest quintiles of 2-fluorene 
and 3-fluorene had a 45.4% (P = 0.0027) and 46.7% (P = 0.0035) greater PR of T2D than 
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those with lower levels. There were no significant associations observed for the other 
metabolites and T2D (P > 0.05). 
Certain PAHs influenced the relationship between BMI and hypertension wherein 
normal and overweight individuals in the highest quintiles of 2-fluorene and 3-fluorene 
had a greater PR of hypertension than those with lower levels, while little difference was 
observed in obese individuals (PAH x BMI interactions: P = 0.0004 and P = 0.017 
respectively, Figure 2). Further, for a given BMI, those in the highest quintiles of 1-
napthalene and 2-naphthalene had a 15.3% (P = 0.0059) and 15.6% (P = 0.021) greater 
PR of hypertension respectively compared to those with lower levels. No significant 
associations were observed with 1-pyrene or the phenanthrene metabolites and 
hypertension (P > 0.05).  
PAH biomarkers influenced the relationship between BMI and dyslipidemia 
wherein overweight and obese individuals in the highest quintiles of 1-phenanthrene had 
a greater PR of dyslipidemia than those with lower levels, while little difference was 
observed in normal weight individuals (PAH x BMI interaction: P = 0.0026, Figure 3). 
For a given BMI, those in the highest quintiles of 2-fluorene, 3-fluorene and 1-
naphthalene had a 9.3% (P = 0.02), 13.0% (P = 0.0035) and 7.2% (P = 0.046) greater PR 
of dyslipidemia than those with lower levels. No significant associations were observed 
for dyslipidemia and the other metabolites (P > 0.05). 
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DISCUSSION 
 To our knowledge, we are one of the first to examine the association between 
PAH and obesity in adults with PAH being observed to be both positively and negatively 
associated with BMI. In addition, we are one of the first to examine the relationship 
between PAH and MetS, diabetes hypertension, and dyslipidemia independent of BMI. 
We observed the naphthalene and fluorene metabolites to have significant deleterious 
associations with a number of different health risk independent of BMI, while two of the 
phenanthrene biomarkers and 1-pyrene were not related to any health conditions. These 
findings bring to light the potentially detrimental impact of certain PAH biomarkers on 
obesity and metabolic conditions in the general population. 
The literature on BMI and PAH relationships has been limited to date (87). 
Contrary to previous studies conducted on children (87), we observed both a positive and 
negative association between PAH and BMI. BMI is widely believed to be correlated 
with higher adipose tissue concentrations.  Since PAH is stored in fat tissue (32), it is 
hypothesized that more PAH will be stored in individuals with higher BMIs leading to 
lower excretion levels of PAH in urine and feces. This may be a plausible explanation to 
the negative associations we observed between the metabolites and BMI.  Though no 
causal relationship can be extrapolated here, the weak association between BMI and PAH 
may be a modest contributing factor to the increasing prevalence of obesity. In addition to 
the BMI and PAH relationship, we observed PAH to be more strongly associated with the 
other health risks examined. 
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MetS is recognized to be related with numerous risk factors including circulatory 
disease (93), which is of increasing relevance since more than 20% of the US adult 
population are affected by MetS (94). We observed 2 PAH metabolites to be associated 
with a greater risk of MetS, independent of BMI. This significant association raises 
additional questions about the influence of PAH on health, which warrants further 
investigation.  
In addition to MetS, 3 other major risk factors of CVD were examined in this 
study including T2D. A recent study reports naphthalene biomarkers, and 2-phenanthrene 
to be associated with T2D independent of BMI (95). Consistent with previous literature, 
we observed that regardless of BMI, individuals with high levels of naphthalene had a 41-
49% greater risk of T2D compared to those with lower levels. However, we did not detect 
any significant associations between 2-phenanthrene and T2D. In addition, we observed 
the fluorene biomarkers to augment the risk of T2D, independent of BMI, whereas 
previous literature (95) failed to demonstrate such a relationship. These differences in 
findings may in part be due to the different T2D definitions used in the studies, where, in 
addition to high glycohemoglobin, the current study also included individuals with blood 
glucose levels ≥ 7 mmol/L. Furthermore, NHANES updated their data regarding PAH 
which allowed us to examine two addition survey years. In summary, PAH is associated 
with T2D and may be a factor related to its high prevalence. Considering the pre-
established health risks commonly related with T2D (96), these findings warrant the 
attention of researchers and clinicians caring for T2D patients to monitor PAH levels.  In 
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addition, we still require research to enhance our limited knowledge of the underlying 
physiological effects of each PAH biomarker on T2D. 
 To our knowledge, no studies have examined the relationship between 
hypertension and PAH. We observed that, regardless of BMI, individuals with high levels 
of 1-naphthalene and 2-naphthalene have a 15% greater PR of hypertension. In addition, 
high levels of certain PAH biomarkers may be modestly associated with hypertension in 
normal and overweight individuals but not in the obese. These novel results raise 
questions about the potential mechanisms of action that allow for greater hypertension 
risks. A study on rodents suggests that PAH may result in carcinogenesis and 
atherogenesis by increasing inflammation and the size of plaques in arteries (97). 
However, the proportion of PAH excreted by obese individuals may be lower than 
normal weight or overweight individuals because the obese may be storing more of the 
PAH. Thus, the observations from this study examining urinary metabolites of PAH and 
not fat storage, could be underestimating the true health effects of PAH in the obese 
population. 
 Although studies on potential PAH and hypertension relationships are non-
existent, one study was found to investigate the effects of environmental pollutants on 
lipid markers. In general, the study reports high levels of fluorene biomarkers to be 
associated with unfavorable HDL levels (56). In the current study, we observed that those 
with high levels of fluorene had a 7-13% greater PR of dyslipidemia, independent of 
BMI. These findings are consistent with the previous study as both observed PAH to be 
related to a disadvantageous lipid profile (56), however, we also observed 1-naphthalene 
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to be related to dyslipidemia whereas no such findings were demonstrated in previous 
literature. Furthermore, high levels of 1-phenanthrene augment the risk of dyslipidemia in 
the overweight and obese but not normal weight individuals. It is important to note that 
the present study observed PAH to be associated with the condition of dyslipidemia as a 
whole, which uses cut-offs that have been proven to increase the risk of cardiac-related 
illnesses. Therefore, this method of measurement may be a better indicator of risk as 
opposed to isolating each component. 
 We are aware of a number of potential limitations of our study.  Our cross-
sectional study design does not allow for extrapolation of causal or temporal relationships 
between PAH and health risk. In addition, examined urinary concentrations of PAH are 
reflective of immediate or short-term PAH exposure and do not account for the PAH 
levels stored in fatty tissue. Therefore we still require studies to investigate PAH levels in 
fat tissue as it relates to health risk over an extended period of time. Finally, we were 
unable to study some of the more toxic and carcinogenic PAHs including benzopyrene 
(32,35), as NHANES failed to collect such data. However, an important strength of this 
study is the fact that we are one of the first to examine the association between metabolic 
conditions and PAH, independent of BMI. In addition, all multivariable statistics models 
were adjusted for smoking status, which allowed us to account for the underlying 
variability caused by cigarette smoke inhalation. Furthermore, these results are 
representative and generalizable to the general adult population. 
 In conclusion, PAH is associated with greater risk of cardiometabolic health 
conditions independent of BMI. Those with high levels of PAH have a greater risk of 
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MetS, hypertension, dyslipidemia and T2D. This suggests future studies should explore 
the physiological mechanisms of each biomarker on health.   
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Table 1: Participant characteristic and metabolic syndrome status 
  
No MetS         
(n = 4894) 
MetS             
(n = 1265) 
P 
Age (years) 43.8 ± 0.3 56.3 ± 0.5 <0.0001 
BMI (kg/m
2
)  27.6 ± 0.1 32.0 ± 0.3 <0.0001 
Creatinine (mg/dL) 125.7 ± 1.6 120.2 ± 2.6 0.0350 
Sex, n (% male) 2446 (50.0) 683 (54.0) 0.0140 
Ethnicity, n (%) 
  
<0.0001 
   White 2317 (47.3) 639 (50.5) 
 
   Black 1074 (21.9) 271 (21.4) 
 
   Other 1503 (30.7) 355 (28.1) 
 
Smoker, n (%) 
  
0.0104 
   Never 2642 (54.0) 601 (47.5) 
 
   Current 1117 (22.8) 264 (20.9) 
 
   Past 1135 (23.2) 400 (31.6) 
 
PIR, n (% below poverty) 916 (18.7) 243 (19.2) 0.9585 
Hypertension, n (%) 1444 (29.5) 991 (78.3) <0.0001 
Type 2 Diabetes, n (%) 303 (6.2) 594 (47.0) <0.0001 
Dyslipidemia n, (%) 2545 (52.0) 1238 (97.9) <0.0001 
PAH metabolites (ng/L)   
  
    1-naphthalene 28935 ± 9935 29478 ± 4550 0.9755 
    2-naphthalene 7658 ± 278 7627 ± 398 0.9351 
    2-fluorene 711 ± 27 751 ± 52 0.3449 
    3-fluorene 359 ± 15 366 ± 29 0.7769 
    1-phenanthrene 238 ± 8 251 ± 17 0.3720 
    2-phenanthrene 96 ± 4 104 ± 9 0.3019 
    3-phenanthrene 192 ± 10 189 ± 18 0.8993 
    1-pyrene 182 ± 9 174 ±15 0.5496 
Abbreviations: MetS, metabolic syndrome; BMI, body mass index; PIR, poverty index 
ratio 
Continuous variables are presented as mean ± SE 
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Table 2: The association between PAH and BMI 
PAH metabolite 
Regression Parameter 
Estimate   
Partial Pearson r 
 
  β ± SE P   r P 
    1-naphthalene 0.22 ± 0.1 <0.01 
 
0.028 0.03 
    2-naphthalene 0.26 ± 0.1 0.04 
 
0.002 0.90 
    2-fluorene -0.04 ± 0.1 0.79 
 
-0.043 <0.01 
    3-fluorene -0.43 ± 0.2 0.05 
 
-0.082 <0.01 
    1-phenanthrene 0.13 ± 0.1 0.21 
 
0.017 0.19 
    2-phenanthrene 0.38 ± 0.1 <0.01 
 
0.051 <0.01 
    3-phenanthrene -0.10 ± 0.1 0.31 
 
-0.008 0.52 
    1-pyrene -0.02 ± 0.1 0.79   -0.016 0.20 
PAH is standardized 
All regression models were weighted 
All regression and partial Pearson r values are adjusted for age, sex, ethnicity, 
PIR, smoking status and creatinine 
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CHAPTER 5.0 GENERAL DISCUSSION 
 The overall health of an individual is dependent on a number of different 
components including physical, psychological, and environmental. There has been a rise 
in cardiometabolic conditions including obesity, T2D, dyslipidemia and hypertension that 
are augmenting the risk of CVD and mortality in the general population. With the 
growing prevalence and the subsequent economic burden related to these conditions, 
researchers have been compelled to explore the myriad of diverse risk factors related to 
health. Prior to this thesis, it was unclear whether PAH or the less studied OP pesticides 
were associated with cardiometabolic risk factors, independent of BMI, however, the 
studies in this thesis have attempted to address the gaps in the literature pertaining to 
these exposures. 
Based on the first manuscript, we can conclude that various types of OP can have 
either detrimental or advantageous associations with health for a given BMI in the 
general population. However, based on these results, it is important to note that each 
metabolite may relate differently to health risk.  We recommend future researchers to 
focus on the mechanisms that may explain these observations.  
The relation between PAH and cardiac health has been previously established. 
However, research is lacking in regards to the relationship between PAH and risk factors 
of CVD. In the second manuscript, we observed PAH to be correlated negatively and 
positively with obesity. Further, PAH is associated with an increased risk of MetS, 
hypertension, T2D and dyslipidemia, independent of BMI, and may alter how BMI is 
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related to health. These novel findings further our understanding of PAH on health and 
expand the limited body of literature pertaining to this environmental pollutant. 
A couple of important limitations must be addressed. First, both studies were 
cross-sectional in nature so we are unable to infer causation. Second, urinary OP and 
PAH levels were measured through one spot-urine sample. A more precise measurement 
indicative of average exposure may have been obtained if there were spot-urine samples 
acquired on a number of different days, however NHANES is not a longitudinal study 
and hence did not provide follow-up data collection. A great strength of this study is the 
use of tandem mass chromatography/mass spectrometry method of quantifying urinary 
OP exposure levels which has been demonstrated to be a highly sensitive and selective 
(61,98–100) method of measurement. This is especially important when measuring 
population levels of OP exposure.  In addition, PAH was measured using a combination 
of solid-phase extraction, capillary gas chromatography and high-resolution mass 
spectrometry which have also been established to result in highly reliable measurements 
(101–103). 
These studies help grow the modest body of literature pertaining to OP, PAH, 
obesity and health. Based on these findings, it is clear that certain chemicals the general 
population comes into contact with may be risk factors for disease. These risk factors 
may help explain the recent rise in cardiometabolic conditions.  However, the 
environmental exposures examined in this thesis are only a small fraction of the 
chemicals that individuals come into contact with on a daily basis, and their biological 
impact is not fully understood. Therefore, it is hoped that the studies in this manuscript 
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raise the interest of researchers in the environmental science and cardiometabolic health 
fields to help provide further insight on the impact of environmental pollutants on health 
and the mechanistic pathways involved.  
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